bioprocessing
(3)
Eric Abbate
Eric Abbate is a synthetic-biology scientist turned CEO who led Solar Biotech, a Virginia-based startup building solar-powered, water-neutral fermentation plants to make biodesigned cosmetics, food ingredients and bioelectronic components. A UC Berkeley-trained molecular and cell biologist, he ran high-throughput genome-engineering and analytical biochemistry teams at Inscripta and was corresponding author on a widely cited paper on optimizing strain engineering for industrial-scale production. He steered Solar Biotech from lab science toward a modular 'BioNodes' manufacturing model before the company entered Chapter 11 in 2024 with plans to sell its assets and reboot.
Fabian Gerlinghaus
Fabian Gerlinghaus is the Co-Founder and CEO of Cellares, a South San Francisco biotech company building the world's first Integrated Development and Manufacturing Organization (IDMO) for cell therapy. An aerospace engineer turned life-science entrepreneur, he co-founded Cellares in 2019 after spotting a critical gap: FDA-approved CAR-T therapies were sitting ready while patients died on waitlists because manufacturing couldn't scale. His Cell Shuttle platform — a fully automated, factory-in-a-box system processing 16 patient batches simultaneously — has attracted $630M in funding, a $380M partnership with Bristol Myers Squibb, and FDA's Advanced Manufacturing Technology designation. TIME magazine named it one of 2025's most important inventions.
Yuyo Llamazares Vegh
Yuyo Llamazares Vegh is the CEO and Co-Founder of Stämm, a San Francisco-based biotech company reinventing biomanufacturing through miniaturized 3D-printed microfluidic bioreactors. A native of Argentina with a background in agricultural engineering and bioprocesses from the University of Buenos Aires, Yuyo co-founded Stämm in 2016 alongside his cousin Federico D'Alvia Vegh after spotting a fundamental gap between biology's potential and the outdated tools available to harness it. Stämm's platform - desktop-sized, modular, and scalable - is designed to make the production of biologics, cell therapies, and gene therapies accessible and repeatable at any scale. The company has raised over $17 million including a Series A led by Varana Capital with participation from Draper Associates and SOSV's IndieBio, and has attracted former Merck KGaA CEO Stefan Oschmann to its board. Yuyo was selected as an Endeavor Entrepreneur in 2023.